Gap Inc V.GAP

in the Yukon News.....

[piconator2]

PharmaGap is coming to Whitehorse!!!

Rober t C. McInnis, President & Chief Execut ive Of f icer

Bob joined PharmaGap in December 2004. Prior to this, Bob was the Director of Financial Programs at World Heart Corporation, dealing with various financial structuring programs including

responsibility for U.S. and Canadian capital markets regulatory affairs. Previously, Bob was president of SC Stormont Corporation and was involved in the corporate financial management for the

Ottawa Senators Hockey Club and The Corel Centre. Before that, Bob was employed at SHL Systemhouse Inc., at the time, Canada’s largest computer system integration company where he held a

number of key financial management roles including corporate structuring, and mergers and acquisitions activity. Bob is a chartered accountant and holds a Bachelor of Mathematics degree from

the University of Waterloo.

Dr . Kenneth K. Sokol l , PhD, VP Cl inical Development

Dr. Sokoll has served in an executive role in the drug development industry since 2003 and has served in a variety of product development roles since 1994 in Canada, the United States and France. He

has assumed full responsibility for clinical trials, clinical trial protocol development and delivery, as well as development of strategies for clinical development of lead drug candidates, preclinical

development, and chemistry, manufacturing and control requirements, among others.

Roder ick M. (Rod) Bryden, Chai rman of the Board

Mr. Bryden is Chairman of PharmaGap and the founder and Chairman of SC Stormont Inc., a business advisory company which participates in the development of small to mid-sized Canadian

businesses. He is also the President of Plasco Energy Group and a director of Clearford Industries. He was the former Chairman and CEO of WorldHeart Corporation, Paperboard Industries, Systemhouse

Ltd. and was the CEO of Terrace Corporation, the principal owner of the Ottawa Senators NHL hockey franchise. Mr. Bryden has taught law at the University of Saskatchewan and was a senior federal

government official. He has a B.A. (Hon. Economics) from Mount Allison University (New Brunswick), LLB from the University of New Brunswick and LLM from the University of Michigan, Ann Arbor.

PharmaGap Inc. is a bio-pharma company developing proprietary drug compounds which target the underlying cell

signaling pathways known to be the root cause of a range of human diseases, and specifically cancer. This type of drug

therapy focuses on restoring normal, healthy cell cycles, thereby slowing growth and killing cancer cells and the tumors

they form. This approach contrasts with the primary focus of current cancer care, which is centered on excision (where

possible) followed by chemotherapy and radiation therapy – put simply: first cut, then poison. One such cell signaling

enzyme is a cellular protein family called Protein Kinase C (“PKC”). Scientists and medical researchers from around the

world have demonstrated the strong link between the PKC family of enzymes and many serious diseases, including

cancer, diabetes and inflammatory diseases like arthritis. PharmaGap’s drug compounds are designed from first principles

to inhibit abnormal activity of PKC found in human disease conditions.

PharmaGap’s business model is to out-license the results of its drug program to Big Pharma once clinical trials are

commenced, or earlier if a compelling valuation can be achieved for shareholders.

PharmaGap has completed the discovery phase of development for GAP-107B8, and has over the past 12 months worked

with recognized, independent testing organizations and collaborators to validate its lead cancer drug GAP-107B8. These

organizations included the National Cancer Institute in Washington, Memorial Sloan-Kettering Cancer Centre in New York,

and the Ottawa Hospital Research Institute. GAP-107B8’s compelling bioactivity, efficacy and excellent safety profile has

been demonstrated in vitro and in animal models.

Testing performed at the Ottawa Hospital Research Institute (OHRI), the National Cancer Institute (NCI), and the Memorial

Sloan-Kettering Cancer Center have all demonstrated GAP-107B8’s strong potential for the growth inhibition and

destruction of a wide spectrum of cancer types. Some of the most striking results showed a dose dependent effect of the

drug in causing cancer cell death: Prostate Cancer up to 100%; Melanoma up to 92%; and Colon Cancer up to 86%.

With this work close to completion, the Company is now embarking on the development of the clinical trial program for

GAP-107B8 and generation of data required for the application to commence clinical trials, with the objective of

commencing clinical trials in 2012.

Because of the strong support PharmaGap has received from investors in this area, company management will be

holding a presentation in Whitehorse on August 3rd. In attendance will be Bob McInnis (CEO), Dr. Ken Sokoll (VP Clinical

Development), and Rod Bryden (Chairman).

Location: Gold Rush Inn – Town Hall Meeting Room

Date: Tuesday, August 3rd

Time: 7:00 – 9:00 PM (Doors open at 6:00 PM)

Whether you are a current shareholder or not we have all been touched by the horrors of cancer in one way or another.

If you would like to know more about the cutting edge research that is ongoing in the War on Cancer you are more than

welcome to attend what will be a very informative presentation.